Janux Therapeutics, Inc.
JANX
$28.80
$1.937.18%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -100.00% | -95.07% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -100.00% | -95.07% | |||
| Cost of Revenue | 11.78% | 24.94% | |||
| Gross Profit | -14.48% | -202.87% | |||
| SG&A Expenses | -53.50% | 125.89% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -20.01% | 59.69% | |||
| Operating Income | 19.03% | -159.31% | |||
| Income Before Tax | 27.95% | -370.87% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 27.95% | -370.87% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 27.95% | -370.87% | |||
| EBIT | 19.03% | -159.31% | |||
| EBITDA | 19.31% | -165.33% | |||
| EPS Basic | 30.74% | -369.47% | |||
| Normalized Basic EPS | 30.75% | -369.30% | |||
| EPS Diluted | 30.74% | -369.47% | |||
| Normalized Diluted EPS | 30.75% | -369.30% | |||
| Average Basic Shares Outstanding | 4.03% | 0.33% | |||
| Average Diluted Shares Outstanding | 4.03% | 0.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
